Sweden's ContextVision Q1 revenue rises 8.5%, margin improves

ContextVision AB

08/05/2026 07:10

Overview

Sweden medical imaging software firm's Q1 revenue rose 8.5% yr/yr to 28.5 mln SEK

Adjusted EBITDA margin improved to 20.5% from 8.1% on higher license sales and cost control

Company extended share buyback program until May 2026

Outlook

Company says it will continue to execute on priorities and capitalise on emerging opportunities

ContextVision sees potential benefit as Chinese procurement activity normalises after recent slowdown

Company reports active pipeline of technical and commercial follow-up activities in coming months

Result Drivers

LICENSE SALES & CONTRACTS - Increased license sales and new client contracts contributed to revenue growth in Q1

COST CONTROL - Improved profitability reflected disciplined cost control and more efficient allocation of consultant resources

MARKET STABILISATION - Underlying revenue growth of 7.4% was achieved in a stabilising market, despite negative FX effects and changes in revenue recognition timing

Company press release: ID:nMFN3wdCZ9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 28.50 mln
SEK 27 mln (1 Analyst)
Q1 EBITDA
SEK 2.80 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for ContextVision AB is NOK3.30, about 8.8% below its May 7 closing price of NOK3.62

The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 33 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)